Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in systemic lupus erythematosus

References

• Balabanov R, Lisak D, Beaumont T, Lisak RP, Dore-Duffy P. (2001). Expression of urokinase plasminogen activator receptor on monocytes from patients with relapsing-remitting multiple sclerosis: effect of glatiramer acetate (copolymer 1). Clin Diagn Lab Immunol 8:1196–1203.
   PubMedGoogle Scholar
• Behrendt N, Stephens RW. (1998). The urokinase receptor. Fibrinolysis and Proteolysis 12:191–204.
   Google Scholar
• Danø K, Behrendt N, Brünner N, Ellis V, Ploug M, Pyke C. (1994). The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 8:189–203.
   Google Scholar
• de Carvalho JF, Hanaoka B, Szyper-Kravitz M, Shoenfeld Y. (2007). C-Reactive protein and its implications in systemic lupus erythematosus. Acta Reumatol Port 32:317–322.
   PubMed Web of Science ®Google Scholar
• Griffiths B, Mosca M, Gordon C. (2005). Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol 19:685–708.
   PubMed Web of Science ®Google Scholar
• Hochberg MC. (1997). Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725.
   PubMed Web of Science ®Google Scholar
• International Council for Standardization in Haematology (Expert Panel on Blood Rheology). (1993). ICSH recommendations for measurement of erythrocyte sedimentation rate. J Clin Pathol 46:198–203.
   PubMed Web of Science ®Google Scholar
• Liou LB. (2001). Serum and in vitro production of IL-1 receptor antagonist correlate with C-reactive protein levels in newly diagnosed, untreated lupus patients. Clin Exp Rheumatol 19:515–523.
   PubMed Web of Science ®Google Scholar
• Liou LB. (2003). Different monocyte reaction patterns in newly diagnosed, untreated rheumatoid arthritis and lupus patients probably confer disparate C-reactive protein levels. Clin Exp Rheumatol 21:437–444.
   PubMed Web of Science ®Google Scholar
• May AE, Neumann FJ, Schömig A, Preissner KT. (2000). VLA-4 (alpha(4)beta(1)) engagement defines a novel activation pathway for beta(2) integrin-dependent leukocyte adhesion involving the urokinase receptor. Blood 96:506–513.
   PubMed Web of Science ®Google Scholar
• Ostergaard C, Benfield T, Lundgren JD, Eugen-Olsen J. (2004). Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome. Scand J Infect Dis 36:14–19.
   PubMed Web of Science ®Google Scholar
• Ostrowski SR, Ullum H, Goka BQ, Høyer-Hansen G, Obeng-Adjei G, Pedersen BK, Akanmori BD, Kurtzhals JA. (2005). Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome. J Infect Dis 191:1331–1341.
   PubMed Web of Science ®Google Scholar
• Riisbro R, Christensen IJ, Høgdall C, Brünner N, Høgdall E. (2001). Soluble urokinase plasminogen activator receptor measurements: influence of sample handling. Int J Biol Markers 16:233–239.
   PubMed Web of Science ®Google Scholar
• Rønne E, Pappot H, Grøndahl-Hansen J, Høyer-Hansen G, Plesner T, Hansen NE, Danø K. (1995). The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 89:576–581.
   PubMed Web of Science ®Google Scholar
• Russell AI, Cunninghame Graham DS, Shepherd C, Roberton CA, Whittaker J, Meeks J, Powell RJ, Isenberg DA, Walport MJ, Vyse TJ. (2004). Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet 13:137–147.
   PubMed Web of Science ®Google Scholar
• Sier CF, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N, Frigerio L, Ferrari A, Danø K, Brünner N, Blasi F. (1998). The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 58:1843–1849.
   PubMed Web of Science ®Google Scholar
• Sier CF, Sidenius N, Mariani A, Aletti G, Agape V, Ferrari A, Casetta G, Stephens RW, Brünner N, Blasi F. (1999). Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance. Lab Invest 79:717–722.
   PubMed Web of Science ®Google Scholar
• Sjöwall C, Eriksson P, Almer S, Skogh T. (2002). Autoantibodies to C-reactive protein is a common finding in SLE, but not in primary Sjögren’s syndrome, rheumatoid arthritis or inflammatory bowel disease. J Autoimmun 19:155–160.
   PubMed Web of Science ®Google Scholar
• Stephens RW, Pedersen AN, Nielsen HJ, Hamers MJ, Høyer-Hansen G, Rønne E, Dybkjaer E, Danø K, Brünner N. (1997). ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 43:1868–1876.
   PubMed Web of Science ®Google Scholar
• Kravitz MS, Shoenfeld Y. (2006). Autoimmunity to protective molecules: is it the perpetuum mobile (vicious cycle) of autoimmune rheumatic diseases? Nat Clin Pract Rheumatol 2:481–490.
   PubMedGoogle Scholar
• Tarui T, Mazar AP, Cines DB, Takada Y. (2001). Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction. J Biol Chem 276:3983–3990.
   PubMed Web of Science ®Google Scholar
• ter Borg EJ, Horst G, Limburg PC, van Rijswijk MH, Kallenberg CG. (1990). C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: a prospective longitudinal study. J Rheumatol 17:1642–1648.
   PubMed Web of Science ®Google Scholar
• Toldi G, Bíró E, Szalay B, Stenczer B, Molvarec A, Rigó J, Vásárhelyi B, Bekõ G. (2011). Soluble urokinase plasminogen activator receptor (suPAR) levels in healthy pregnancy and preeclampsia. Clin Chem Lab Med 49:1873–1876.
   PubMed Web of Science ®Google Scholar
• Toldi G, Bekó G, Kádár G, Mácsai E, Kovács L, Vásárhelyi B, Balog A. (2012). Soluble urokinase plasminogen activator receptor (suPAR) in the assessment of inflammatory activity of rheumatoid arthritis patients in remission. Clin Chem Lab Med 0:1–6.
   Google Scholar